Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine.

Szczegóły
Abstrakt

Tytuł:: Perspectives of Methotrexate-Based Radioagents for Application in Nuclear Medicine.
Autorzy:: Halik PK; Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Koźmiński P; Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Gniazdowska E; Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Źródło:: Molecular pharmaceutics [Mol Pharm] 2021 Jan 04; Vol. 18 (1), pp. 33-43. Date of Electronic Publication: 2020 Nov 30.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Washington, DC : American Chemical Society, c2004-
MeSH Terms:: Methotrexate/*chemistry
Methotrexate/*therapeutic use
Radiopharmaceuticals/*chemistry
Radiopharmaceuticals/*therapeutic use
Antirheumatic Agents/chemistry ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/metabolism ; Folate Receptors, GPI-Anchored/metabolism ; Folic Acid/metabolism ; Humans ; Nuclear Medicine/methods
References:: Ann Rheum Dis. 2016 Dec;75(12):2157-2165. (PMID: 26920997)
Cancer Biother Radiopharm. 2008 Oct;23(5):571-9. (PMID: 18999930)
Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. (PMID: 19221750)
Nucl Med Biol. 2010 Apr;37(3):277-88. (PMID: 20346867)
Cochrane Database Syst Rev. 2019 Jan 18;1:CD012722. (PMID: 30656673)
Mod Pathol. 2011 Sep;24(9):1221-8. (PMID: 21572402)
Hell J Nucl Med. 2012 May-Aug;15(2):120-4. (PMID: 22833858)
Bioconjug Chem. 2000 Mar-Apr;11(2):253-7. (PMID: 10725102)
Biochem Pharmacol. 1992 Nov 3;44(9):1898-901. (PMID: 1449544)
Biochim Biophys Acta. 1976 Nov 2;448(4):531-50. (PMID: 823974)
Arthritis Res Ther. 2012 Jun 08;14(3):R138. (PMID: 22682496)
Cancer Res. 1972 Jul;32(7):1506-11. (PMID: 5030579)
J Neurooncol. 1994;21(2):107-12. (PMID: 7861186)
Environ Toxicol Pharmacol. 2000 Mar 1;8(3):191-196. (PMID: 10925072)
J Leukoc Biol. 2014 May;95(5):797-808. (PMID: 24399840)
Blood. 1949 Feb;4(2):160-7. (PMID: 18107667)
J Microencapsul. 1995 Jul-Aug;12(4):437-46. (PMID: 8583318)
J Neurooncol. 1997 Apr;32(2):111-23. (PMID: 9120540)
Biochemistry. 1995 Apr 25;34(16):5660-5. (PMID: 7727426)
Immunity. 2007 Jul;27(1):145-59. (PMID: 17613255)
Molecules. 2013 Apr 29;18(5):5005-31. (PMID: 23629756)
J Biol Chem. 1968 Oct 10;243(19):5007-17. (PMID: 5303004)
Eur J Cancer. 1994;30A(3):363-9. (PMID: 8204360)
Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109766. (PMID: 31349410)
Br J Pharmacol. 2010 May;160(1):101-15. (PMID: 20331607)
Mol Aspects Med. 2013 Apr-Jun;34(2-3):373-85. (PMID: 23506878)
Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15180-8. (PMID: 23934049)
Cancer Res. 1995 Feb 1;55(3):478-81. (PMID: 7834611)
Cancer Res. 1965 Aug;25(7):1008-17. (PMID: 4954195)
Blood. 1949 Feb;4(2):168-71. (PMID: 18107668)
Cancer Chemother Pharmacol. 2008 Nov;62(6):937-48. (PMID: 18283461)
Biochem Pharmacol. 1989 Sep 15;38(18):2995-3002. (PMID: 2783154)
Curr Pharm Des. 2012;18(8):1058-83. (PMID: 22272825)
J Biol Chem. 1992 Jun 5;267(16):11038-45. (PMID: 1597445)
Arthritis Rheum. 1998 Jan;41(1):48-57. (PMID: 9433869)
Biosci Rep. 1997 Aug;17(4):415-27. (PMID: 9367057)
Lancet. 1979 Jan 20;1(8108):166-7. (PMID: 84197)
J Clin Invest. 1985 Sep;76(3):907-12. (PMID: 2413074)
J Biol Chem. 1985 Aug 15;260(17):9720-6. (PMID: 2410416)
J Membr Biol. 1984;79(3):285-92. (PMID: 6471097)
J Nucl Med. 1996 Jan;37(1):105-7. (PMID: 8543977)
Expert Opin Drug Deliv. 2008 Mar;5(3):309-19. (PMID: 18318652)
Drug Deliv. 2016 Sep;23(7):2327-2337. (PMID: 25475953)
J Thorac Cardiovasc Surg. 2001 Feb;121(2):225-33. (PMID: 11174727)
Nucl Med Biol. 2011 Oct;38(7):1019-28. (PMID: 21982573)
Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):BP99-106. (PMID: 14989222)
Gene. 2000 Nov 27;258(1-2):117-25. (PMID: 11111049)
Cancer Res. 1965 Aug;25(7):1018-24. (PMID: 4284746)
Biochem J. 1986 May 15;236(1):193-200. (PMID: 2431676)
Oncogene. 2003 Oct 20;22(47):7431-57. (PMID: 14576850)
J Nucl Med. 2005 Aug;46(8):1356-67. (PMID: 16085595)
Cancer. 1994 May 1;73(9):2432-43. (PMID: 7513252)
Nature. 2013 Aug 22;500(7463):486-9. (PMID: 23851396)
Br J Cancer. 1977 Nov;36(5):608-17. (PMID: 588422)
Cancer Res. 1978 Mar;38(3):706-12. (PMID: 414833)
Clin Cancer Res. 2003 May;9(5):1917-26. (PMID: 12738750)
J Clin Invest. 1998 Jul 15;102(2):322-8. (PMID: 9664073)
Biochem Biophys Res Commun. 1973 May 1;52(1):27-34. (PMID: 4197190)
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6256-64. (PMID: 15448015)
J Immunol. 2012 Aug 15;189(4):1946-54. (PMID: 22778395)
J Biol Chem. 1995 Apr 7;270(14):7842-9. (PMID: 7713875)
J Clin Invest. 1982 Aug;70(2):351-60. (PMID: 6178756)
Arthritis Rheum. 1999 Aug;42(8):1609-16. (PMID: 10446858)
Cancer Res. 1992 Jun 15;52(12):3396-401. (PMID: 1596899)
Kidney Int. 1992 Jan;41(1):50-5. (PMID: 1593862)
Biochemistry. 2018 Dec 11;57(49):6780-6786. (PMID: 30452231)
Bioconjug Chem. 1993 Jan-Feb;4(1):25-33. (PMID: 8431509)
J Clin Invest. 1976 Feb;57(2):534-8. (PMID: 1062383)
Anal Biochem. 2005 Mar 15;338(2):284-93. (PMID: 15745749)
J Clin Invest. 1993 Dec;92(6):2675-82. (PMID: 8254024)
Int J Mol Sci. 2015 Jan 13;16(1):1772-90. (PMID: 25590303)
Blood. 2015 May 28;125(22):3466-76. (PMID: 25887778)
Nature. 2014 Apr 24;508(7497):483-7. (PMID: 24739963)
Br J Cancer. 1992 Jun;65(6):838-44. (PMID: 1616855)
Cancer Immunol Immunother. 1987;25(1):1-6. (PMID: 3496155)
Cancer Res. 1992 Dec 1;52(23):6708-11. (PMID: 1330299)
Nature. 2001 Dec 20-27;414(6866):916-20. (PMID: 11780065)
Ann Surg Oncol. 2008 Mar;15(3):889-99. (PMID: 18181001)
J Biol Chem. 1999 Apr 16;274(16):11086-91. (PMID: 10196192)
Drug Deliv. 2001 Jul-Aug;8(3):125-34. (PMID: 11570592)
Nucl Med Biol. 2012 Aug;39(6):864-70. (PMID: 22445744)
Biochem J. 1999 Aug 15;342 ( Pt 1):143-52. (PMID: 10432311)
Mol Pharmacol. 2008 Sep;74(3):854-62. (PMID: 18524888)
Mol Med Rep. 2018 Feb;17(2):2442-2448. (PMID: 29207127)
Mol Pharmacol. 1995 Sep;48(3):459-71. (PMID: 7565626)
Cancer Biother Radiopharm. 2006 Feb;21(1):49-60. (PMID: 16480331)
Mol Pharm. 2013 Jul 1;10(7):2543-57. (PMID: 23683251)
J Biol Chem. 1980 Apr 25;255(8):3254-7. (PMID: 6965938)
Ann Clin Biochem. 1978 Nov;15(6):331-4. (PMID: 736493)
Cancer. 1999 Jan 15;85(2):348-57. (PMID: 10023702)
Int J Pharm. 1999 Oct 15;188(1):39-47. (PMID: 10528081)
Cancer Res. 1985 Mar;45(3):1092-6. (PMID: 3971363)
Cancer Res. 2009 Dec 15;69(24):9395-403. (PMID: 19951991)
Eur J Cancer. 2004 Oct;40(15):2287-92. (PMID: 15454255)
Int J Cancer. 2007 Sep 1;121(5):938-42. (PMID: 17487842)
Cell. 2006 Dec 1;127(5):917-28. (PMID: 17129779)
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4771-5. (PMID: 2052557)
J Pharmacokinet Biopharm. 1977 Oct;5(5):421-33. (PMID: 925879)
J Clin Invest. 1986 Sep;78(3):760-70. (PMID: 3745437)
Cancer Biother Radiopharm. 1998 Jun;13(3):177-84. (PMID: 10850353)
Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881-5. (PMID: 3860829)
Ann Rheum Dis. 2020 Jun;79(6):685-699. (PMID: 31969328)
Hell J Nucl Med. 2013 Jan-Apr;16(1):33-7. (PMID: 23529391)
J Clin Invest. 1948 Jul;27(4):539. (PMID: 18935160)
Cancer Res. 1995 Sep 1;55(17):3795-802. (PMID: 7641196)
Cancer Res. 1993 May 15;53(10 Suppl):2368-73. (PMID: 8485723)
Cancer Treat Rep. 1977 Dec;61(9):1647-56. (PMID: 597817)
Int J Cancer. 1997 Apr 22;74(2):193-8. (PMID: 9133455)
Cancer Res. 1985 Oct;45(10):4732-4. (PMID: 3875399)
Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):775-82. (PMID: 10498396)
Bioconjug Chem. 1997 Sep-Oct;8(5):673-9. (PMID: 9327130)
Cancer Res. 2002 Nov 15;62(22):6434-7. (PMID: 12438230)
Clin Chim Acta. 1974 Dec 17;57(3):263-7. (PMID: 4474066)
Int J Mol Sci. 2020 May 14;21(10):. (PMID: 32423175)
Clin Chem. 1978 Sep;24(9):1534-8. (PMID: 688614)
Contributed Indexing:: Keywords: anticancer drug; methotrexate; radiopharmaceuticals
Substance Nomenclature:: 0 (Antirheumatic Agents)
0 (Folate Receptors, GPI-Anchored)
0 (Radiopharmaceuticals)
935E97BOY8 (Folic Acid)
YL5FZ2Y5U1 (Methotrexate)
Entry Date(s):: Date Created: 20201130 Date Completed: 20211005 Latest Revision: 20211005
Update Code:: 20240105
PubMed Central ID:: PMC7788572
DOI:: 10.1021/acs.molpharmaceut.0c00740
PMID:: 33251808
: Czasopismo naukowe

Full Text Finder

Methotrexate is a gold standard among disease modifying antirheumatic drugs and is also extensively used clinically in combination with oncological therapies. Thus, it is not surprising that nuclear medicine found an interest in methotrexate in the search for diagnostic and therapeutic solutions. Numerous folate-related radiopharmaceuticals have been proposed for nuclear medicine purposes; however, methotrexate radioagents represent only a minority. This imbalance results from the fact that methotrexate has significantly weaker affinity for folate receptors than folic acid. Nevertheless, radiolabeled methotrexate agents utilized as a tool for early detection and imaging of inflammation in rheumatoid arthritis patients gave promising results. Similarly, the use of multimodal MTX-release nanosystems may find potential applications in radiosynovectomy and theranostic approaches in folate receptor positive cancers.

Informacja